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The role of acupoint stimulation as an adjunct
therapy for lung cancer: a systematic review
and meta-analysis
Hai-Yong Chen1†, Shi-Guang Li2†, William CS Cho3* and Zhang-Jin Zhang1*
Abstract
Background: Lung cancer is the leading cause of death in cancer patients. Clinical studies showed that a variety of
acupoint stimulations have been extensively used for lung cancer patients, including needle insertion, injection with
herbal extraction, plaster application, and moxibustion. However, the role of acupoint stimulation in lung cancer
treatment was not fully reviewed.
Methods: In the present study, we conducted a systematic review and meta-analysis on the role of acupoint
stimulation in lung cancer treatment by electronic and manual searching in seven databases, including Ovid
(Ovid MEDLINE, AMED, CAB Abstracts, EMBASE), EBSCOhost research databases (Academic Search premier, MEDLINE,
CIHAHL Plus), PreQuest (British Nursing Index, ProQuest Medical Library, ProQuest Dissertations & Theses A&I,
PsycINFO), and ISI web of knowledge (Web of Science, BIOSIS Citation Index, Biological Abstracts, Chinese Science
Citation Database), CNKI, Wanfang Data, and CQVIP.
Results: Our study showed that acupoint stimulation has strong immunomodulatory effect for lung cancer patients
as demonstrated by the significant increase of IL-2, T cell subtypes (CD3+ and CD4+, but not CD8+ cells), and
natural killer cells. Further analysis revealed that acupoint stimulation remarkably alleviates the conventional
therapy-induced bone marrow suppression (hemoglobin, platelet, and WBC reduction) in lung cancer patients, as
well as decreases nausea and vomiting. The pooled studies also showed that acupoint stimulation can improve
Karnofsky performance status, immediate tumor response, quality of life (EORCT-QLQ-C30), and pain control of
cancer patients.
Conclusions: Acupoint stimulation is found to be effective in lung cancer treatment, further confirmatory
evaluation via large scale randomized trials is warranted.
Keywords: Acupuncture, Chinese medicine, Lung cancer, Systematic review, Meta-analysis
Background
Acupuncture has been widely used for more than three
thousand years in China. It is one of the key treatment
modalities in traditional Chinese medicine (TCM), which
is also based on the Yin-Yang, Channel and Collateral
Theories. Accordingly to TCM theories, Yin-Yang
imbalance is the basis of diseases and stimulation of
certain acupoints along the collaterals can nurture the
qi (or vital energy) and rebalance Yin-Yang in the body.
Recently, acupuncture has been widely developed into a
variety form of acupoint stimulation, including needle
insertion, injection with herbal extract, plaster appli-
cation, and moxibustion, etc. [1]. Previous studies have
shown that acupoint stimulation can be used to treat a
variety of diseases and symptoms, e.g. insomnia [2], de-
pression [3], and pain [4]. In recent decades, TCM is
regarded as a complementary therapy to cancer patients
worldwide [5-7]. A number of literatures have reported
that acupoint stimulation may be effective on symptom
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management [8,9], reduction of chemotherapy-induced
side effects [10-12], and quality of life improvement
[13] in cancer patients.
Lung cancer is a leading cause of cancer mortality with
1.37 million deaths in 2008 worldwide. It is the most
prevalent cancer in male and the fourth prevalent cancer
in female. Conventional therapies for lung cancer include
surgery, radiotherapy, chemotherapy, and targeted thera-
pies (e.g. erlotinib and bevacizumab). Recently, the use of
alternative and complementary therapies is increasingly
widespread [14,15]. We have previously found that Chinese
herbal medicine, as an adjunct therapy, has advantage in
the reduction of side effects and improvement of symp-
toms in patients with non-small cell lung carcinoma [16].
Some clinical studies have also reported the use of acu-
point stimulation as a treatment for lung cancer [17,18].
However, the role of acupoint stimulation in treating lung
cancer is not thoroughly evaluated. Thus, we conducted
a systematic review and meta-analysis on the efficacy
of acupoint stimulation for lung cancer patients in the
present study.
Methods
Selection criteria
Included studies have to meet all of the following
criteria:
1. Studies claimed as random allocation or showed
the baseline data without significant difference
(age, gender, and severity) among the intervention
and control groups.
2. Studies had to use acupoint stimulation as the
adjunct intervention, or had to use acupoint
stimulation as the primary studying objective or
evaluating purpose.
3. Studies had at least one control group with
conventional therapies, placebo, or other appropriate
controls.
4. Studies investigated at least one of the outcomes of
interest listed below:
i) Immunomodulation: changes in CD3, CD4, CD8
levels of T cell, natural killer (NK) cells, and IL-2
levels.
ii) Bone marrow suppression: changes in
hemoglobin, platelets, and white blood cells
(WBCs).
iii)Conventional therapy-induced side effect: nausea
and vomiting. Judgment of vomiting grade was
based on WHO toxicity reaction: grade 0: no
nausea and vomiting; grade I: nausea; grade II:
casual vomiting, not requiring medication; grade
III: frequent vomiting, requiring medication;
grade IV: serious vomiting, uncontrolled with
medication.
iv) Immediate tumor response: number of patients
with complete response (CR) or partial response
(PR) evaluated with the WHO scale.
v) Performance status: the changes of Karnofsky
performance status (KPS) scores.
vi)Other quality of life assessments,
e.g. EORTC-QLQ-C30.
Databases
Four major search engines were retrieved, including:
1. OVID® (Ovid MEDLINE 1946 to January 2013,
AMED 1985 to 2013, CAB Abstracts 1910 to
January 2013, EMBASE 1996 to February 2013).
2. EBSCOhost research databases (Academic Search
premier, MEDLINE, CIHAHL Plus, all to
January 2013).
3. PreQuest (British Nursing Index 1994 to January
2013, ProQuest Medical Library from starts to
January 2013, ProQuest Dissertations & Theses A&I
from starts to January 2013, PsycINFO 1806 to
January 2013).
4. ISI web of knowledge (Web of Science® 1956 to
January 2013, BIOSIS Citation Index 2006 to January
2013, Biological Abstracts® 1980 to 2012, Chinese
Science Citation Database 1989 to January 2013).
The Chinese electronic databases were as the follows:
1. CNKI (China Academic Journals Full-text Database
1979 to January 2013, China Doctoral Dissertations
Full-text Database 1984 to January 2013, China
Masters’ Theses Full-text Database 1984 to January
2013, China Proceedings of Conference Full-text
Database 1953 to January 2013).
2. Wanfang Data (1990 to January 2013).
3. CQVIP (1989 to January 2013).
Search strategy
Electronic databases were searched using the following
strategy:
Searching terms: (acupuncture OR acupressure OR
acupoint OR massage OR meridian OR moxibustion OR
moxa) AND (pulmonary cancer OR pulmonary carcinoma
OR pulmonary adenocarcinoma OR pulmonary squamous
cell carcinomas OR pulmonary neoplasms OR pulmonary
nodules OR pulmonary tumor OR lung cancer OR lung
carcinoma OR lung adenocarcinoma OR lung squamous
cell carcinoma OR lung neoplasms OR lung nodules OR
lung tumor OR non-small-cell lung carcinoma OR non-
small-cell-lung carcinoma OR NSCLC OR small-cell lung
carcinoma OR small-cell-lung carcinoma OR SCLC).
Chinese language database was retrieved with similar
search strategy. “AND” and “OR” are Boolean operators.
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Risk bias assessment
Risk bias of studies was assessed using the Cochrane Risk
of Bias Assessment Tool (http://handbook.cochrane.org/,
part 2, chapter 8). All trials were reviewed by at least two
reviewers (HYC and SGL) and any disagreement was re-
solved through the involvement of a third reviewer in con-
sensus conferences.
Data synthesis
All analyses were performed with RevMan version 5.2 to
quantify and compare the efficacy outcomes of the treat-
ment versus the control groups. Dichotomous data were
reported as relative ratio (RR) whereas continuous data
were reported as standardized mean difference (SMD) ±
standard deviation (SD). The random-effect model was
employed when the study of heterogeneity (I2) was large
than 50%, otherwise a fix-effect model was used when the
I2 was less than 50%. To test the heterogeneity, subgroup
analysis was performed according to the types of acupoint
stimulation (needle insertion, acupuncture injection with
herbs, acupoint plaster application, and moxibustion). The
Z-test was used to compare the overall effects of the treat-
ment groups and the control groups, differences were
considered to be statistically significant when P < 0.05.
Results and discussion
993 abstracts were retrieved with 155 duplications. 154
studies in full text were further examined. A total of 31
studies satisfied the selection criteria and were analyzed in
the present study (Figure 1) and their characteristics are
listed in Table 1. Acupoint stimulation varies from needle
insertion, pressure, plaster application, and moxibustion
to herbal extraction injection on the acupoints. The most
commonly used acupoints were listed in Table 2. The risk
of bias in the included studies was assessed as shown in
Figure 2. The risk of bias in each study was shown in
(Additional file 1: Table S1).
Immunomodulation
A remarkable increase in CD3+ T cell level was reported
in patients treated with acupoint stimulation (SMD, 0.41
[95% CI, 0.20 to 0.62], P = 1E-4, 9 studies, 370 patients)
Figure 1 Flow chart of study selection.
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Table 1 Characteristics of included studies
Studies No. of
patients
Acupuncture group Control group intervention Assessment of outcomes Duration
Acupoints Intervention
Cai and Wu [19] 80 Fixed points: ST36 Acupuncture + GP and Ondansetrontdn
Dexamethasone
GP and Ondansetron
Dexamethasone
Nausea and vomiting 8 weeks
Chen [20] 32 Fixed points: ST36 and BL23 Astragalus injection in acupuncture
points + NP/CE and Huangqilifei
decoction
NP/CE and Huangqilifei
decoction
Tumor response; immunomodulation
(CD3+, CD4+, CD4/CD8); KPS;
survival rate; chemotoxicity
8 weeks
Chen [21] 60 Fixed points: BL13, LU1, LU9,
ST36, PC6, etc.
Acupuncture + TP/GP and Chinese
herbs by syndrome differentiation
TP/GP and Chinese herbs by
syndrome differentiation
Tumor response; clinical symptom
improvement; immunomodulation
8 weeks
Chen [22] 60 Fixed points: RN4 Ginger moxibustion + general nursing
care
General nursing care Sleep quality and WBCs 10 days
Chen et al. [23] 50 Fixed points: LU9, PC6, ST36,
BL23, DU14
Acupuncture + CAP/EP CAP/EP NK and leukocyte cells 8 weeks
Ding [24]a 86 Fixed points : LU9, BL13, ST36,
ST40, SP3, BL20, BL43 (bilateral)
Acupuncture + Fu zhen gan fei
decoction
Fu zhen gan fei Decoction Clinical symptom improvement;
WBCs; Hb; Plt; KPS
8 weeks
Ding [25]b 32 Fixed points: ST36, PC6 Acupuncture + cis-platinum based
chemotherapy and ondansetron
Cis-platinum based
chemotherapy and
ondansetron
Nausea and vomiting 4 weeks
Fan & Wei [26] 80 Fixed points: ST36 Vitamin B6 acupoint injection + NP/TP
chemotherapy combined with
ondansetron
NP/TP chemotherapy
combined with ondansetron
Nausea and vomiting; KPS Not reported
Gu et al. [27] 40 Fixed points: ST36, RN4, BL23,
DU4
Acupoint plaster application + Chinese
herbs (unclear ingredient)
Chinese herbs (unclear
ingredient)
Immunomodulation (CD3+, CD4+,
CD4/CD8), IL-2
8 weeks
He & Lou [28] 49 PC6, LI10, SP46, SP4 (bilateral);
RN12 (unilateral); auricular point:
liver, spleen, shen men, jiao gan
Acupoint stimulation + EP with
ondansetron
EP with ondansetron Nausea and vomiting; chemotoxicity 3 days
Huang [29] 40 LU9, BL13, BL17, ST36 (bilateral) Crude herb moxibustion (Semen
Brassicae, Manchurian Wildginger,
Ephedra sinica Stapf ) + cis-platinum
based chemotherapy
Cis-platinum based
chemotherapy
Chemotoxicity; living quality; body
weight; clinical symptoms; tumor
size; immunomodulation (CD3+, CD4
+, CD4/CD8)
6 weeks
Huang et al. [30] 80 PC6, ST21, ST36 (bilateral) Acupoint plaster application + NP/GP
with ondansetron
NP/GP with ondansetron Survival; KPS; clinical symptom
improvement; chemotoxicity
3 weeks
Jiang et al. [31] 43 BL23, ST36 (bilateral); DU4, RN4
(unilateral)
Acupoint plaster application decoction
(of herbal medicine) + gemcitabine/
pemetrexed/docetaxel
Gemcitabine/pemetrexed/
docetaxel
Time to progression (TTP); quality of
life
8 weeks
Li [32] 60 BL13, BL15, BL17 (bilateral) Acupoint plaster application with
decoction (of Semen Brassicae,
Manchurian Wildginger, Ephedra sinica
Stapf) + Diprophylline
Diprophylline Dyspnea valuated by numeric scale 7 days
Lin et al. [33] 83 BL17 (bilateral) Acupuncture + NP/EP NP/EP Chemotoxicity (reduction of WBCs,
Hb, Plt) ; KPS
10 days
Lin et al. [34] 80 four flowers acupoints: BL17,
BL19 (bilateral)
Moxibustion + NP with Granisetron
hydrochloride
NP with Granisetron
Hydrochloride
Chemotoxicity (reduction of WBCs,
Hb, Plt)
10 days
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Table 1 Characteristics of included studies (Continued)
Lin [34] 60 ST36, BL13 (bilateral) Acupoint injection (Chuan ke zhi) +
Aminophylline injection
Aminophylline injection KPS; immunomodulation (CD3+, CD4
+); clinical symptoms improvement
2 weeks
Liu & Wang [35] 60 RN12 Acupoint plaster application with herbal
medicine (Pinellia Tuber and Syzygium
aromaticum, etc.) + cis-platinum based
chemotherapy + Granisetron hydrochlor-
ide injection
Cis-platinum based
chemotherapy + Granisetron
Hydrochloride injection
KPS; appetite score 3 days
Lou [36] 51 bilateral: ST36, RN4, LU5 Acupoint magnet + GP GP Immunomodulation (CD3+, CD4+,
CD4/CD8)
2 weeks
Ou Yang et al. [37] 69 RN8 Moxibustion with salt + NP/GP NP/GP Clinical symptom improvement;
immunomodulation (CD3+, CD4+,
CD11+); nausea and vomiting
4 ~ 8 weeks
Qiao et al. [38] 56 Ashi acupoints, ST36, KI1 Millimeter wave treatment + Gu se fang
granules
Gu se fang granules Clinical symptom improvement; KPS 4 weeks
Shi et al. [39] 32 ST36, BL23, BL20, RN6, RN4, LU10,
LI10, LI4, SI3, PC4, PC6, SJ6
(bilateral)
Acupuncture + general anesthesia General anesthesia Immunomodulation (CD3+, CD4+,
CD4/CD8)
Not reported
Tao et al. [40] 100 ST36, PC6 (bilateral); RN4 Acupoint plaster application +
chemotherapy with metoclopramide or
ondansetron
Chemotherapy with
metoclopramide or
ondansetron
Nausea and vomiting 7 days
Wang [41] 60 Four flowers acupoints: BL17,
BL19 (bilateral)
Moxibustion + NP NP TNF-α, IL-2, WBCs; nausea and vomit-
ing; KPS
7 days
Xu [42] 60 Four flowers acupoints: BL17,
BL19 (bilateral)
Fire needle therapy + GP/DP combined
with ondansetron
GP/DP combined with
ondansetron
Immunomodulation (CD3+, CD4+,
CD4/CD8); TNF-α, IL-2; KPS
7 days
Xu et al. [43] 45 ST36, DU14 Acupoint injection (Radix Sophorae
Flavescentis extraction) + anti-tumor
Chinese herbs
Anti-tumor Chinese herbs KPS; blood cells; chemotoxicity
(WBCs, Hb, Plt)
4 weeks
Xuan et al. [44] 60 BL13 (bilateral); DU14 Acupoint plaster application + traditional
Chinese medicine
Traditional Chinese medicine Immunomodulation (CD3+, CD4+,
CD4/CD8); KPS
4 weeks
Zhang [45] 60 Four flowers acupoints: BL17,
BL19 (bilateral)
Moxibustion + GP/DP combined with
ondansetron
GP/DP combined with
ondansetron
Immunomodulation (CD3+, CD4+,
CD4/CD8), TNF-α, IL-2, CSF; KPS
7 days
Zhang & Cheng.
[46]
40 ST36, BL13 Chuan ke zhi injection combined with
Aminophylline injection to acupoint +
routine treatment for symptoms
Routine treatment for
symptoms
Lung function, clinical symptoms;
immunomodulation (CD3+, CD4+,
CD4/CD8)
2 weeks
Zhou et al. [47] 15 ST36, BL23, BL20, RN6, RN4, LU10,
LI10, LI4, SI3, PC4, PC6, SJ6
(bilateral)
Acupuncture + general anesthesia General anesthesia Immunomodulation (CD3+, CD4+,
CD4/CD8)
Not reported
Zhou et al. [48] 35 Acupoint selection treatment
based on syndrome
differentiation
Abdominal acupuncture + routine
treatment for symptoms
Routine treatment for
symptoms
KPS, EORTC-QLQ-C30 4 weeks
CAP, cyclophosphamide + adriamycin + cisplatinum; CE, carboplatin and etoposide; CSF, colony stimulating factors; DP, docetaxel + cisplatinum; EP, VP-16 + cisplatinum; GP, gemcitabine + cisplatinum; Hb, hemoglobin;
KPS, Karnofsky performance score; NP, vinorelbine + cisplatinum; Plt, platelet; TP, paclitaxel + cisplatinum; WBCs, white blood cells.
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(Figure 3A), and the heterogeneity test indicated no sig-
nificant difference among those studies [20,21,27,29,
36,39,42,46,47]. Subgroup analysis showed that acupoint
needle insertion (SMD, 0.35 [95% CI, 0.04 to 0.66],
P = 0.03, 4 studies) and acupoint injection with herbs
(SMD, 0.59 [95% CI, 0.12 to 1.07], P = 0.01, 2 studies)
had advantage in improving CD3+ while acupoint
plaster application (SMD, 0.22 [95% CI, -0.19 to 0.64],
P = 0.29, 2 studies) had no significant advantage in
CD3+ improvement.
We also observed an improvement in the CD4+ T cell
level (SMD, 0.61 [95% CI, 0.42 to 0.80], P < 1E-5, 10
studies, 459 patients) (Figure 3B) [20,21,27,36,37,39,42,
44,46,47]. Subgroup analysis showed that acupoint needle
insertion (SMD, 0.50 [95% CI, 0.19 to 0.82], P = 0.002, 4
studies) and acupoint injection with herbs (SMD, 0.72
[95% CI, 0.17 to 0.83], P = 0.003, 2 studies) had advantage
in improving CD4+ while acupoint plaster application
(SMD, 0.50 [95% CI, 0.17 to 0.83], P = 0.003, 3 studies)
had no significant advantage in CD4+ improvement.
The CD8+ T cell level in patients treated with acu-
puncture has shown no significant difference compared
with the control group (SMD, 0.0 [95% CI, -0.19 to
0.19], P = 1.0, 10 studies, 459 patients) (Additional file 2:
Figure S1A) [20,21,27,36,37,39,42,44,46,47]. Subgroup
analysis showed that acupoint injection with herbs
(SMD = −0.67, 95% CI = -1.15 to -0.20, p = 0.006, 2 stu-
dies) had advantage in lowing CD8+, acupoint plaster
application (SMD, 0.21 [95% CI, -0.18 to 0.61], P = 0.29,
2 studies) had advantage in upregulating CD8+, and
acupoint needle insertion (SMD, 0.0 [95% CI, -0.31 to
0.31], P = 0.99, 4 studies) had no significant advantage.
Heterogeneity test indicated a significant difference
among the acupoint needle insertion subgroup. After
further removing any study among them, the acupoint
needle insertion group still showed no significant alter-
nation compared with the control groups.
As shown in Additional file 2: Figure S1B, the pooled
studies indicated that acupoint stimulation can increase
chemotherapy-induced NK cell reduction compared to the
control group (SMD, 0.59 [95% CI, 0.21 to 0.97], P = 0.002,
3 studies, 114 patients) [20,23,47]. Among them, two stu-
dies used needle insertion and the left used acupoint injec-
tion with herb extraction.
Four studies used IL-2 as the outcome measurement
to assess the efficacy of acupoint stimulation as an ad-
junct therapy for lung cancer [27,41,42,45]. The acupoint
stimulation group showed a slightly better outcome than
the control (SMD, 0.28 [95% CI, 0.01 to 0.55], P = 0.04, 4
studies, 220 patients) (Additional file 2: Figure S1C).
There was no significant difference in the baseline of
CD3+, CD4+, CD8+ T cells, NK cells, and IL-2 between
the acupoint stimulation and control groups as shown in
Table 3.
Bone marrow suppression
The pooled study showed that the prevention against
hemoglobin reduction was significantly in favor of the
acupoint stimulation group (SMD, 0.40 [95% CI, 0.17 to
0.63], P = 7E-4, 5 studies, 296 patients) (Additional file 2:
Figure S2A) [24,42,43,45,49]. There was no significant
heterogeneity among these studies (P = 0. 64).
The number of patients with decreased platelets was
significantly reduced in the acupoint stimulation group
(SMD, 0.28 [95% CI, 0.05 to 0.51], P = 0.02, 5 studies, 296
patients) (Additional file 2: Figure S2B) [24,42,43,45,49].
The inhibition of WBCs in lung cancer patients with
acupoint stimulation was significant reduced (SMD, 0.93
[95% CI, 0.44 to 1.42], P < 2E-4, 8 studies, 519 patients)
[22,24,33,34,42,43,45,49], but there was a prominent
Table 2 Commonly used acupoints
Acupoints Counts Frequency (%)
ST36 (Zu San Li ) 19 64.5
PC6 (Nei Guan) 8 25.8
BL17 (Ge Shu) 8 25.8
BL13 (Fei Shu) 7 22.6
RN4 (Guan Yuan) 7 22.6
BL23 (Shen Shu) 6 19.4
Figure 2 Risk of bias assessment among included studies.
Chen et al. BMC Complementary and Alternative Medicine 2013, 13:362 Page 6 of 14
http://www.biomedcentral.com/1472-6882/13/362
Figure 3 Immunomodulation of acupuncture in lung cancer patients. (A) CD3+ T cells; (B) CD4+ T cells.
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heterogeneity among these studies (P = 1E-5) (Additional
file 2: Figure S2C). Sensitivity test showed that removing
any of the studies did not alter the patterns, however, there
is still heterogeneity among the studies (data not shown).
As shown in Table 3, there was no significant differ-
ence in the baseline of hemoglobin, platelets, and WBCs
between the acupoint stimulation and control groups.
Nausea and vomiting
As shown in Figure 4, the occurrence of chemotherapy-
induced nausea and vomiting at Grade II-IV was re-
markably reduced in the acupoint stimulation group
compared to the control group (RR, 0.46 [95% CI, 0.37-0.51],
P= 1E-5, 8 studies, 501 patients) [19,20,25,26,28,41,42,45].
Subgroup analysis showed that acupoint needle insertion,
acupoint injection with herbs, and moxibustion sig-
nificantly attenuated the grade of nausea and vomiting
(P = 0.02, P = 0.005, and P = 0.01, respectively).
Clinical efficacy
The immediate tumor response indicated that acupoint
stimulation had a significant advantage compared to the
control group (RR, 1.54 [95% CI, 1.15 to 2.07], P = 0.004, 3
studies, 148 patients) (Figure 5A) [20,38,49]. Two studies
used acupoint injection with herb extraction and one used
microwave treatment in the assessed studies.
The pooled KPS Scale showed a significant increase of
clinical performance in the acupoint stimulation group
compared to the control group (SMD, 0.76 [95% CI, 0.42
to 1.10], P < 1E-4, 9 studies, 508 patients) as shown in
Figure 5B [25,33,38,41,42,44,45,48,49]. However, the hete-
rogeneity study showed a significant difference among
these studies. Sensitivity test indicated a significant in-
crease of KPS in the acupoint stimulation group with re-
moval of anyone study in the nine studies. Subgroup
analysis showed that acupoint injection with herb
extraction, plaster application, and moxibustion had
significant advantage in KPS without heterogeneity in
studies (P = 0.0002, P = 0.001, and P < 0.0001 respec-
tively). Acupoint needle insertion also had no advantage
in KPS, but Zhou et al.’s study in the needle insertion
group showed a high heterogeneity (P = 0.51, I2 = 79%)
compared to the other two studies [48]. The baseline of
KPS showed no significant difference between the acu-
point stimulation group and the control group (Table 3).
EORTC-QLQ-C30 also showed a total favorable score
in the acupoint stimulation group compared to the con-
trol group (SMD, 0.47 [95% CI, 0.04 to 0.90], P = 0.03, 2
studies, 85 patients) as shown in Figure 6A [31,48]. In
addition, the Visual Analog Scale had a significant im-
provement in the acupoint stimulation group compared
to the control group (SMD, -1.13 [95% CI, -1.58 to −0.69],
P < 1E-5, 2 studies, 92 patients) [20,32] (Figure 6).
Discussion
In the present study, we systematically reviewed the role
of acupoint stimulation in lung cancer management. Our
results showed that acupoint stimulation has immuno-
modulatory effect for lung cancer patients, which was
demonstrated by a significant increase of IL-2, CD3+ and
CD4+ T cells, NK cells, but not CD8+ T cells. Further ana-
lysis also revealed that acupoint stimulation remarkably
reduces the conventional therapy-induced bone marrow
suppression, enhances hemoglobin and platelets in lung
cancer patients, and decreases the chemotherapy-induced
nausea and vomiting. In addition, the pooled studies also
showed that acupoint stimulation has an advantage in the
improvement of performance status, immediate tumor
response, and quality of life (EORCT-QLQ-C30).
We found that acupoint stimulation enhances T cell
subtype CD3+ and CD4+ cells, but not CD8+ cells. Sub-
group analysis indicated that acupoint insertion and injec-
tion with herb extraction are able to elevate the total
T cells (CD3+) and T helper cells (CD4+) in lung cancer
Table 3 Baseline of included studies
Index Standard mean difference 95% CI Heterogeneity Overall effect (P value)
Immunomodulation
CD3+ T cells 0.07 [−0.30, 0.44 ] I2 = 67% Z = 0.35 (P = 0.72)
CD4+ T cells −0.04 [−0.31, 0.24] I2 = 52% Z = 0.27 (P = 0.79)
CD8+ T cells −0.01 [−0.19, 0.18] I2 = 0% Z = 0.08 (P = 0.94)
Natural killer cells −0.38 [−1.39, 0.62] I2 = 79% Z = 0.75 (P = 0.45)
IL-2 0.05 [−0.21, 0.32] I2 = 0% Z = 0.39 (P = 0.70)
Bone marrow suppression
Hemoglobin 0.04 [−0.19, 0.27] I2 = 0% Z = 0.37 (P = 0.71)
Platelets 0.06 [−0.17, 0.29] I2 = 0% Z = 0.53 (P = 0.60)
White blood cells 0.07 [−0.11, 0.24 ] I2 = 0% Z = 0.75 (P = 0.45)
Clinical efficacy
Karnofsky performance score −0.08 [−0.25, 0.09] I2 = 0% Z = 0.93 (P = 0.35)
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patients. Acupoint plaster application enhances CD4+ T
cells, but not CD3+ T cells. CD8+ is cytotoxic T cells
which are one of the most effective immune cells to kill
tumor cells [50]. Interestingly, our study showed that
acupoint stimulation has no significant effect on the
increase of CD8+ T cells compared to the control group.
Subgroup analysis showed that acupoint needle inser-
tion has no significant effect, while acupoint injection
with herbs decreases CD8+ T cells and plaster applica-
tion increases CD8+ T cells in lung cancer patients.
Figure 4 Effective responses of nausea and vomiting (vomiting grade II to IV).
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Figure 5 Clinical efficacy. (A) Tumor response; (B) KPS.
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Although some studies have shown that acupuncture may
upregulate CD8+ expression in patients [51,52], there may
be various mechanisms for the immunomodulatory effects
of acupoint stimulation lung cancer patients. T helper
cells (CD4+) have four subtypes, including Th1, Th2, Treg,
and Th-17 cells. IL-23 is a newly identified cytokine that
has close association with Th17. On the other hand, IL-23
has been shown to impair antitumor CD8+ T cells and
dendritic cells transduced with IL-23 have the ability to
trigger strong antitumor activity [50].
More importantly, our findings have indicated that acu-
point stimulation upregulates IL-2 in lung cancer patients.
It is in line with another study that acupuncture can en-
hance IL-2 expression by stimulation of acupoint ST36 in
rats [53]. As shown in Table 2, ST36 is the most common
acupoint used for lung cancer patients. Previous study has
shown that IL-2 is necessary for the growth, proliferation,
and differentiation of T cells [54]. A recent study has also
demonstrated that IL-2 controls the balance between
Th-17 and Treg cells in the tumor microenvironment
[55]. It has been hypothesized that acupuncture may also
upregulate NK cells in lung cancer patients. A number of
studies have demonstrated that acupuncture is a strong
immunomodulator of NK cells in animals and human
[56-60]. Upregulation of NK cells may contribute to the
antitumor effect in cancer patients [61].
Anemia, thrombocytopenia, and pancytopenia are the
most common symptoms of bone marrow suppression
during chemotherapy or radiotherapy. Our findings indi-
cated that acupuncture reduces conventional therapy-
induced bone marrow suppression, e.g. increase of WBCs,
hemoglobin, and platelets, which is in accordance with
other findings that acupuncture can improve bone mar-
row suppression during chemotherapy [62]. Although the
mechanism remains largely unknown, previous studies
have provided some possible mechanisms, for examples,
acupuncture induces the erythropoietin expression [63]
and bone marrow megakaryocytes [62]. Moreover, upreg-
ulation of IL-2 by acupuncture promotes the mature of T
cells [54]. Subgroup analysis showed that acupoint needle
insertion, injection with herb extraction, and moxibustion
may play different roles in modulating WBCs, hemo-
globin, and platelets.
Reduction of side effects (SEs) is the main goal for using
commentary therapies during conventional cancer treat-
ments. Our previous studies have shown that Chinese
herbal medicine has the advantage of minimizing chemo-
therapy-induced SEs in colon cancer [7], nasopharyngeal
carcinoma [6], hepatocellular carcinoma [5], and non-
small cell lung cancer [16]. These studies showed an alle-
viation of nausea and vomiting during TCM treatment,
which is in line with our present findings that acupoint
stimulation may reduce nausea and vomiting during lung
cancer treatment. As acupoint stimulation has a neuromo-
dulatory effect on GI motility and the mechanism invol-
ving endogenous opiates, it may be effective in treating
chemotherapy-induced nausea and vomiting [64,65]. On
the other hand, pain, cough, constipation, hair and weight
loss are also common SEs during lung cancer treatment.
However, no pooled data was analyzed due to the lack of
relevant clinical studies. Therefore, whether acupoint
stimulation can reduce these SEs during lung cancer treat-
ment needs to be further explored.
Our finding also showed the enhancement of immedi-
ate tumor response, suggesting that acupoint stimulation
may improve clinical symptoms and performance status.
KPS analysis showed that acupoint stimulation (acupoint
injection, plaster application, and moxibustion) can en-
hance performance status during lung cancer treatment.
EORTC-QLQ-C30 is a questionnaire developed to assess
the quality of life of cancer patients. The analysis of
EORTC-QLQ-C30 showed that acupoint stimulation has
an advantage in the improvement of quality of life. How-
ever, the supplemented questionnaire QLQ-C13 for lung
cancer was not analyzed in this meta-analysis as there
was only one study reporting the results of QLQ-C13.
Although the current evidence indicates that acupoint
stimulation plays a positive role in lung cancer treat-
ment. However, the different forms of acupoint stimula-
tions may play different role in immunomodulation,
Figure 6 Quality of life assessments. QLQ-C30 total score.
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bone marrow suppression, reduction of SEs, and improve-
ment of performance status as demonstrated in our stu-
dies. Nevertheless, it is no doubt that using acupoint
stimulation as an adjunct therapy not only can reduce the
SEs of chemotherapy and radiotherapy, but also can
enhance immunomodulation, attenuate bone marrow
suppression, as well as improve clinical efficacy and
quality of life.
Even with these promising results, there are some limi-
tations for the present study. The frequency and duration
of treatment varied in the included studies from several
days to weeks, which may lead to heterogeneity in the an-
alyzed studies. Moreover, we did not analyze the herbs
used in acupoint injection and plaster application as the
main purpose of this study is to evaluate the effect of acu-
point stimulation as an adjunct therapy for lung cancer.
But we can’t exclude the herb effects in acupoint stimula-
tion (acupoint injection and plaster application). In
addition, there were a variety of control interventions that
may also increase heterogeneity of the included studies.
Besides, the efficacy of acupoint stimulation on the pro-
longation of survival rate for lung cancer patients remains
unexplored. Risk bias study showed that a number of
studies are unclear with high risks in allocation conceal-
ment, blinding of participants and personnel, as well as
outcome assessments. The unclear and high risk of bias in
the included studies weakens the conclusion and well-
designed randomized clinical trials are warranted to con-
firm the efficacy of acupoint stimulation in lung cancer. In
the present study, we also conducted the sensitivity test,
excluding studies with less than three of seven items
marked as low risk from the risk bias assessment table.
The sensitivity test (data not shown) is in line with the
results from the analysis of all the included studies.
Although the included literatures indicate that acupunc-
ture is effective for symptom management, reducing SEs,
and improving immune response in cancer patients, the
underlining mechanism on the efficacy of acupuncture is
mostly unknown and this deserves further exploration by
mechanistic studies. This systematic review also arouses
the need for better designed randomized trials of acu-
puncture for lung cancer patients to support the meaning-
ful findings of the included studies.
Conclusion
Acupoint stimulation is found to be effective in lung can-
cer treatment, further confirmatory evaluation via large
scale randomized trials is warranted.
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